Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cance
Dasatinib is a selective tyrosine kinase receptor inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Dasatinib is usually associated with an instantaneous increase in serum aminotransferase levels during treatment, but only clinically significant acute liver injury is rare.
The hydrate is a monohydrate of dasatinib. It is used to treat chronic, accelerated or bone marrow or lymphocytic chronic myeloid leukemia. Please note that the name "dasatinib" is used to refer to monohydrate (USAN) and anhydrous dasatinib (INN).
Dasatinib binds and inhibits the growth promoting activity of these kinases. Obviously, dacotinib has been shown to overcome the resistance of imidamidine to chronic myeloid leukemia (CML) cells containing mutations in the BCR-ABL kinase domain due to its low affinity for BCR-ABL kinase The SRC family of protein tyrosine kinases interact with a variety of cell surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can be altered by altering the regulation or expression of endogenous proteins as well as by viral-encoded kinase genes
